Table 2 Cox regression analysis assessing variables associated to risk of switch in patients who have experienced inefficacy

Female sex

1.05 [0.57–1.96]

0.85

1.07[0.59–1.95]

0.80

Age at ts/bDMARDs ≥ 6 years

0.73[0.49–1.09]

0.13

0.73[0.48–1.12]

0.15

JIA group:

 o-JIA

 poly-JIA

 ERA/JPsA

 sJIA

1

1.34 [0.61–2.96]

0.90 [0.30–2.60]

2.43 [0.96–6.10]

-

0.46

0.83

0.05

1

1.46 [0.66–3.21]

1.06 [0.34–3.32]

2.43 [1.01–5.89]

-

0.34

0.90

0.04

Year of b/tsDMARDs prescription (≥ 2019)

1.47 [0.35–3.67]

0.12

1.50 [1.01–2.25]

0.04

Concomitant Methotrexate

1.13 [0.61–2.96]

0.83

-

-

Refractory disease

1.45[0.75–2.79]

0.26

-

-